Level Four Advisory Services LLC Cuts Position in Johnson & Johnson (NYSE:JNJ)

Level Four Advisory Services LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,629 shares of the company’s stock after selling 972 shares during the period. Level Four Advisory Services LLC’s holdings in Johnson & Johnson were worth $5,114,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Evolution Wealth Advisors LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at approximately $40,000. Horan Securities Inc. grew its stake in Johnson & Johnson by 122.3% in the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after buying an additional 241 shares in the last quarter. Stuart Chaussee & Associates Inc. grew its stake in Johnson & Johnson by 20.7% in the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after buying an additional 80 shares in the last quarter. FNY Investment Advisers LLC grew its stake in Johnson & Johnson by 594.4% in the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock valued at $64,000 after buying an additional 428 shares in the last quarter. Finally, CKW Financial Group grew its stake in Johnson & Johnson by 18.8% in the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock valued at $105,000 after buying an additional 128 shares in the last quarter. Hedge funds and other institutional investors own 66.85% of the company’s stock.

NYSE:JNJ traded down $1.41 during midday trading on Friday, hitting $139.28. The company had a trading volume of 12,792,432 shares, compared to its average volume of 7,295,138. Johnson & Johnson has a 52-week low of $120.11 and a 52-week high of $148.99. The stock has a fifty day simple moving average of $138.37. The firm has a market cap of $373.54 billion, a P/E ratio of 17.03, a PEG ratio of 2.43 and a beta of 0.70. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.07. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. The company had revenue of $20.02 billion during the quarter, compared to analyst estimates of $19.55 billion. During the same period in the previous year, the business earned $2.06 earnings per share. The firm’s quarterly revenue was up .1% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th were given a $0.95 dividend. The ex-dividend date was Friday, May 24th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 annualized dividend and a yield of 2.73%. Johnson & Johnson’s payout ratio is 46.45%.

A number of research analysts recently weighed in on the stock. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $151.00 to $152.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Raymond James boosted their price target on shares of Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Wells Fargo & Co restated an “outperform” rating and set a $157.00 price target (up from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. Barclays started coverage on shares of Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 price target for the company. Finally, BMO Capital Markets boosted their price target on shares of Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and an average target price of $149.89.

In other Johnson & Johnson news, Director Marillyn A. Hewson purchased 3,000 shares of the stock in a transaction on Tuesday, June 11th. The stock was acquired at an average cost of $139.68 per share, with a total value of $419,040.00. Following the completion of the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $419,040. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.23% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: NASDAQ

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.